Similar articles for PMID: 30065068

Year	Number of Results
2014	11
2015	21
2016	8
2017	25
2018	27
2019	12
2020	10
2021	1
2024	0

1

Hepatitis C Virus Infection in ESKD Patients.

Ladino M, Roth D. Ladino M, et al. Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1735-1737. doi: 10.2215/CJN.03700318. Epub 2018 Jul 31. Clin J Am Soc Nephrol. 2018. PMID: 30065068 Free PMC article. No abstract available.

2

Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.

Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Sun HY, et al. Gut. 2018 Jul;67(7):1342-1350. doi: 10.1136/gutjnl-2017-313832. Epub 2017 Jun 14. Gut. 2018. PMID: 28615303

3

A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.

Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. Lv DD, et al. Eur J Gastroenterol Hepatol. 2019 Mar;31(3):382-388. doi: 10.1097/MEG.0000000000001299. Eur J Gastroenterol Hepatol. 2019. PMID: 30383554

4

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators. Charlton M, et al. Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15. Gastroenterology. 2015. PMID: 25985734 Free article. Clinical Trial.

5

Therapy for hepatitis C--the costs of success.

Hoofnagle JH, Sherker AH. Hoofnagle JH, et al. N Engl J Med. 2014 Apr 17;370(16):1552-3. doi: 10.1056/NEJMe1401508. Epub 2014 Apr 11. N Engl J Med. 2014. PMID: 24725236 No abstract available.

6

'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.

García-Agudo R, Aoufi-Rabih S, Salgueira-Lazo M, González-Corvillo C, Fabrizi F. García-Agudo R, et al. Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27. Int J Artif Organs. 2018. PMID: 29582685

7

A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2014 Nov 10;56(1455):111-2. Med Lett Drugs Ther. 2014. PMID: 25372848 No abstract available.

8

Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.

Graf Einsiedel H, Christiansen H, Wiegand J. Graf Einsiedel H, et al. Pediatr Infect Dis J. 2016 Dec;35(12):1373. doi: 10.1097/INF.0000000000001336. Pediatr Infect Dis J. 2016. PMID: 27832030 No abstract available.

9

Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.

Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements K, Alper CJ, Lenz K, Jeffrey PL. Kouris G, et al. J Manag Care Spec Pharm. 2018 Jul;24(7):591-597. doi: 10.18553/jmcp.2018.24.7.591. J Manag Care Spec Pharm. 2018. PMID: 29952708 Free PMC article.

10

Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients.

Eckman MH, Woodle ES, Thakar CV, Alloway RR, Sherman KE. Eckman MH, et al. Am J Kidney Dis. 2020 Jun;75(6):857-867. doi: 10.1053/j.ajkd.2019.11.005. Epub 2020 Feb 17. Am J Kidney Dis. 2020. PMID: 32081494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year